wikimedia
/
wikidata
/
Login
Register
TriplyDB
Wikidata
Browser
Table
SPARQL
Graphs
1
1
Services
1
1
Assets
0
0
Insights
Schema
BETA
Class frequency
Class hierarchy
Q48185230-D32B46CE-CA34-46B3-BA53-240AD5198FCB
Q48185230-D32B46CE-CA34-46B3-BA53-240AD5198FCB
BestRank
Statement
http://www.wikidata.org/entity/statement/Q48185230-D32B46CE-CA34-46B3-BA53-240AD5198FCB
Phase I dose escalation study of the anti-CD2 monoclonal antibody, siplizumab, with DA-EPOCH-R in aggressive peripheral T-cell lymphomas.
P2860
Q48185230-D32B46CE-CA34-46B3-BA53-240AD5198FCB
BestRank
Statement
http://www.wikidata.org/entity/statement/Q48185230-D32B46CE-CA34-46B3-BA53-240AD5198FCB
rank
NormalRank
type
BestRank
Statement
wasDerivedFrom
94d522316512323c1fbd650f759bd4a30ab05f25
P2860
Upfront VIP-reinforced-ABVD (VIP-rABVD) is not superior to CHOP/21 in newly diagnosed peripheral T cell lymphoma. Results of the randomized phase III trial GOELAMS-LTP95.